Surgery plus chemo versus chemo alone for ovarian cancer relapse
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests whether doing additional surgery to remove visible tumor (“secondary cytoreduction”) before chemotherapy helps compared with chemotherapy alone. It’s for ovarian (or related) cancer that came back after prior PARP inhibitor maintenance and platinum chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your ovarian/peritoneal/fallopian tube cancer has come back (first- or second-line relapse).
- You previously had at least 4 cycles of platinum-based chemotherapy, and the relapse happened more than 6 months later.
- You were on a PARP inhibitor (“PARPi”) maintenance treatment for more than 6 months before the relapse.
- Your initial surgery was able to remove all visible disease (R0 “ideal debulking”).
- Your scans show a limited, isolated recurrence (up to 5 spots) and very little/no fluid in the belly (ascites < 500 mL).
- You’re well enough for surgery and treatment (performance status 0–1) and your blood, kidney, and liver tests are within required ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized (adaptive) chemotherapy plan for people with certain types of ovarian/fallopian tube/peritoneal cancer who already had platinum chemotherapy and a PARP inhibitor. It’s for patients whose cancer came back after (or still responds to) prior platinum treatment and may help delay disease progression.
This trial tests if a second surgery followed by heated chemotherapy delivered directly into the abdomen can help people with ovarian, fallopian tube, or peritoneal cancer whose disease has returned while on a PARP inhibitor.
This trial tests whether adding niraparib (a pill treatment that targets cancer cell DNA repair) after surgery can help people with ovarian cancer that has come back. It focuses on “platinum-sensitive” cases and tries to remove all visible tumor when possible.
This trial tests combining surgery with an immunotherapy drug (sintilimab) for women whose ovarian cancer has returned after initial treatment. It aims to see if this approach can improve outcomes for people with specific tumor markers.
This Phase 3 trial tests whether patients with advanced ovarian, fallopian tube, or primary peritoneal cancer do better with surgery first versus chemotherapy first. It also groups people based on how extensive the cancer is to choose the best approach.
This trial looks at whether removing as much tumor as possible with surgery can help people whose ovarian/peritoneal/fallopian tube cancer comes back quickly after platinum chemotherapy. It targets cases where the recurrence is limited and may be safely removed, then compares outcomes to standard care.
Hear when a new Relapsed Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.